Market ExpansionThe VMAT2i market, in which Ingrezza operates, is growing, and Ingrezza is expected to capture approximately 45-50% of this expanding market.
Market PositionIngrezza remains the market leader for the treatment of tardive dyskinesia and is poised to generate significant sales, providing stable cash flow into 2038.
Product LaunchThe launch of Crenessity, NBIX's second commercial product, is expected to beat expectations and drive growth for the company.